Literature DB >> 1711015

Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria.

D Pye1, S J Edwards, R F Anders, C M O'Brien, P Franchina, L N Corcoran, C Monger, M G Peterson, K L Vandenberg, J A Smythe.   

Abstract

Saimiri sciurus monkeys were immunized at multiple sites with recombinant vaccinia viruses expressing Plasmodium falciparum antigen genes and boosted 4 weeks later. Control monkeys were immunized with a thymidine kinase-negative vaccinia virus mutant. Two weeks later, all of the monkeys were challenged by intravenous inoculation of P. falciparum (Indochina strain) parasites. A group of unimmunized monkeys was challenged in parallel. All of the monkeys that received vaccinia virus recombinants or the control virus produced good anti-vaccinia virus antibody responses. However, those that received a single construct containing ring-infected erythrocyte surface antigen (RESA) given at eight sites did not produce significant antibody to any of the three major RESA repeat epitopes after immunization but were primed for an enhanced antibody response after challenge infection with P. falciparum. Most of the monkeys produced detectable antibodies to the RESA epitopes after challenge infection. One group of monkeys was immunized with four constructs (expressing RESA, two merozoite surface antigens [MSA-1 and MSA-2], and a rhoptry protein [AMA-1]), each given at two sites. While these monkeys failed to produce significant antibody against MSA-2 or AMA-1 after immunization, they produced enhanced responses against these antigens after challenge infection. Immunization involved an allelic form of MSA-2 different from that present in the parasite challenge strain, so that the enhanced responses seen after challenge infection indicated the presence of T-cell epitopes common to both allelic forms. No groups of monkeys showed any evidence of protection against challenge, as determined by examination of the resulting parasitemias.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711015      PMCID: PMC258025          DOI: 10.1128/iai.59.7.2403-2411.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  A cDNA clone expressing a rhoptry protein of Plasmodium falciparum.

Authors:  R L Coppel; A E Bianco; J G Culvenor; P E Crewther; G V Brown; R F Anders; D J Kemp
Journal:  Mol Biochem Parasitol       Date:  1987-08       Impact factor: 1.759

2.  Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.

Authors:  R A Olmsted; R M Buller; P L Collins; W T London; J A Beeler; G A Prince; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

3.  Variation in the precursor to the major merozoite surface antigens of Plasmodium falciparum.

Authors:  M G Peterson; R L Coppel; P McIntyre; C J Langford; G Woodrow; G V Brown; R F Anders; D J Kemp
Journal:  Mol Biochem Parasitol       Date:  1988-01-15       Impact factor: 1.759

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences.

Authors:  R L Coppel; A F Cowman; R F Anders; A E Bianco; R B Saint; K R Lingelbach; D J Kemp; G V Brown
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

6.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

7.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Authors:  G L Smith; B R Murphy; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

9.  Identification of two integral membrane proteins of Plasmodium falciparum.

Authors:  J A Smythe; R L Coppel; G V Brown; R Ramasamy; D J Kemp; R F Anders
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum.

Authors:  H Perlmann; K Berzins; M Wahlgren; J Carlsson; A Björkman; M E Patarroyo; P Perlmann
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  9 in total

1.  Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

Authors:  D E Lanar; J A Tine; C de Taisne; M C Seguin; W I Cox; J P Winslow; L A Ware; E B Kauffman; D Gordon; W R Ballou; E Paoletti; J C Sadoff
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

2.  Humoral and cell-mediated immunity to the Plasmodium falciparum ring-infected erythrocyte surface antigen in an adult population exposed to highly endemic malaria.

Authors:  H P Beck; I Felger; B Genton; N Alexander; F al-Yaman; R F Anders; M Alpers
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

3.  Antibodies to a non-repeat region of Plasmodium falciparum antigen Pf155/RESA in individuals from malaria-endemic areas.

Authors:  A B Siddique; N Ahlborg; M Warsame; P Perlmann; K Berzins
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

4.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

5.  Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus.

Authors:  M Theisen; G Cox; B Høgh; S Jepsen; J Vuust
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

7.  Immunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus.

Authors:  J A Tine; V Conseil; P Delplace; C De Taisne; D Camus; E Paoletti
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

Review 8.  Malaria vaccine development.

Authors:  T R Jones; S L Hoffman
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

9.  Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.

Authors:  David R Cavanagh; Clemens H M Kocken; John H White; Graeme J M Cowan; Kay Samuel; Martin A Dubbeld; Annemarie Voorberg-van der Wel; Alan W Thomas; Jana S McBride; David E Arnot
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.